Monte Rosa Therapeutics (US.GLUE)
Capital Allocation Audit · Period: 2019 – 2026
Key Metrics
US.GLUE · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 105.0% | → |
| ROE | -8.5% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.07 | ↑ |
| Gross Margin | 0.0% | ↓ |
US.GLUE (Monte Rosa Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 105.0% → ROE -8.5% ↓ Cash Conversion - → D/E Ratio 0.07 ↑ Gross Margin 0.0% ↓
Key Metrics
US.GLUE (Monte Rosa Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 105.0% →ROE -8.5% ↓Cash Conversion - →D/E Ratio 0.07 ↑Gross Margin 0.0% ↓Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies